Skip to main content
. 2017 Jun 20;117(4):525–534. doi: 10.1038/bjc.2017.181

Figure 5.

Figure 5

miR-646 regulated GC tumour growth and metastasis by targeting FOXK1 in vivo. (A) Fluorescence images of subcutaneous tumours from mice injected with BGC-823/m-NC, BGC-823/miR-646/FOXK1, or BGC-823/miR-646 cells. (B) Tumour size was measured at 5 days after tumour cell inoculation in each group. ***P<0.01, m-NC vs miR-646/FOXK1; and ****P<0.001, miR-646 vs miR-646/FOXK1. (C) Immunohistochemical (IHC) staining of FOXK1 expression in subcutaneous tumours from mice injected with BGC-823/m-NC, BGC-823/miR-646/FOXK1, or BGC-823/miR-646 cells. (D) Mice were orthotopically transplanted with BGC-823 cells (n=3 in each group). (E) Metastatic cancer tissues were stained with H&E. (F) The number of metastatic loci in the lungs was counted. **P<0.05, m-NC vs miR-646/FOXK1 and miR-646/FOXK1 vs miR-646. (G) The expression of E-cadherin in tumours derived from BGC-823 cells was determined by quantitative PCR. ****P<0.001, m-NC vs miR-646/FOXK1; miR-646 vs miR-646/FOXK1. Scale bars, 200 μm in C and 400 μm in E.